# A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

> **NCT04730258** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Treadwell Therapeutics, Inc** · enrollment: 72 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
- AML
- MDS
- CMML

## Interventions

- **DRUG:** CFI-400945
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT04730258
- **Lead sponsor:** Treadwell Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-16
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04730258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04730258, "A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04730258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*